Interestingly, the 4-day change in ratio of IL-6 to IL-10 (a cytokine with anti-inflammatory effects involved both in innate and adaptive immunity), named the Dublin–Boston score, has proven to be a more reliable tool than IL-6 alone in predicting clinical progression and poor outcome in COVID-19 patients [87,88]. The gene discussed is IL6; the disease is COVID-19.